Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharpe and Dohme receives EU approval for Victrelis

Merck Sharpe and Dohme receives EU approval for Victrelis

21st July 2011

Merck Sharpe and Dohme has been granted European regulatory approval for its first-in-class hepatitis C treatment Victrelis.

The European Commission has provided marketing authorisation for the HCV protease inhibitor, which functions by blocking the ability of the virus to reproduce, as opposed to the standard therapy approach of strengthening immune response.

It has been ratified in combination with peginterferon alfa and ribavirin for adult hepatitis patients with compensated liver disease, who are either previously untreated or have failed to respond to prior therapy.

This approval was based on the strong performance of the drug in phase III clinical trials, which were conducted in the EU and US and involved around 1,500 patients.

Bruno Strigini, president for Merck Sharpe and Dohme in Europe and Canada, said: "Victrelis is the first major advancement for the treatment of chronic hepatitis C approved in the EU in a decade."

Earlier this month, the company announced the launch of a new support kit for UK Muslims with diabetes that are planning to fast during the month of Ramadan.ADNFCR-8000103-ID-800628874-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.